levofloxacin

Phase 2/3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Skin Diseases, Infectious

Conditions

Skin Diseases, Infectious, Cellulitis

Trial Timeline

Jul 1, 1991 → Feb 1, 1993

NCT ID

NCT00257036

About levofloxacin

levofloxacin is a phase 2/3 stage product being developed by Johnson & Johnson for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00257036. Target conditions include Skin Diseases, Infectious, Cellulitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002249	Phase 1	Completed	—	—	HIV Infections
NCT00210886	Phase 3	Completed	Oct 1, 2004	Apr 1, 2006	Urinary Tract Infections
NCT00645437	Phase 1	Completed	Oct 1, 2004	Apr 1, 2006	Renal Diseases
NCT00236652	Phase 3	Completed	Nov 1, 2003	Jun 1, 2005	Maxillary Sinusitis
NCT00044473	Phase 3	Completed	Nov 1, 2002	Jul 1, 2003	Otitis Media
NCT00236522	Phase 3	Completed	Oct 1, 2002	Apr 1, 2004	Sinusitis
NCT00034736	Phase 3	Completed	Aug 1, 2002	Jun 1, 2004	Pneumonia
NCT00236821	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Pneumonia
NCT00236808	Phase 3	Completed	May 1, 2000	Nov 1, 2001	Prostatitis
NCT00249197	Phase 3	Completed	Jan 1, 1997	Jul 1, 1998	Skin Diseases, Bacterial
NCT00269932	Phase 3	Completed	Aug 1, 1993	May 1, 1994	Bronchitis, Chronic
NCT00249210	Phase 3	Completed	Aug 1, 1993	Jul 1, 1994	Sinusitis
NCT00258089	Phase 3	Completed	Jun 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00258102	Phase 3	Completed	Jan 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00257062	Phase 3	Completed	Jan 1, 1993	Apr 1, 1994	Skin Diseases, Infectious
NCT00257036	Phase 2/3	Completed	Jul 1, 1991	Feb 1, 1993	Skin Diseases, Infectious
NCT00257049	Phase 2/3	Completed	Jan 1, 1984	Jan 1, 1995	Pneumonia
NCT00257140	Phase 2/3	Completed	Jun 1, 1931	Jul 1, 1994	Bronchitis

Competing Products

20 competing products in Skin Diseases, Infectious

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	25
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product	Sun Pharmaceutical	Phase 1	33
LY3041658 + Placebo	Eli Lilly	Phase 1	33
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation	Sumitomo Pharma	Phase 1	33
Moisturizer A, F#9155-005	Johnson & Johnson	Pre-clinical	23
levofloxacin	Johnson & Johnson	Phase 3	77
Ceftobiprole	Johnson & Johnson	Phase 1	33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells	Johnson & Johnson	Phase 1	33
Levofloxacin	Johnson & Johnson	Phase 3	77
Ceftobiprole	Johnson & Johnson	Phase 1	33
Levodopa-carbidopa intestinal gel	AbbVie	Phase 3	77
Iressa	AstraZeneca	Phase 2	52
Daptomycin + Vancomycin	AstraZeneca	Phase 3	77
Sarizotan	Merck	Pre-clinical	23
Pembrolizumab + EDP1503	Merck	Phase 2	52
testosterone gel + Comparator: placebo	Merck	Phase 1	33
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)	Merck	Phase 2/3	65
Vancomycin + Daptomycin + Semi-Synthetic Penicillin	Merck	Approved	85
Pembrolizumab + Vismodegib	Merck	Phase 1/2	41

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved

Nicotine Gum + Nicotine PatchApproved

galantamineApproved

IbrutinibApproved

Paliperidone ERApproved